Artes buys tech from Select Vaccines; DecImmune raises $3.2M;

 @FierceBiotech: Alnylam announces 25-30% reduction of workforce. Article | Follow @FierceBiotech

 @JohnCFierce: The only brake on cancer drug pricing right now seems to be competition. Absent that, the sky's the limit. | Follow @JohnCFierce

> The geographical divide in the pharma business is growing ever sharper. New numbers further clarify just why Europe isn't Big Pharma's favorite market--and why drugmakers are flocking to Asia in a new-millennium gold rush, as PharmaTimes reports. Report

> Artes Biotechnology purchased the Anavax virus-like particle technology from Select Vaccines. The technology has been used in flu, malaria and HIV vaccines, and uses artificial virus proteins to create vaccines without the possibility of infection. Artes release

> Cambridge, MA-based DecImmune Therapeutics has closed $3.2 million in finance; $1 million from Astellas Venture Management and $2.2 million from the National Institutes of Health. The company is working on technology to aid in ischemia reperfusion injury. DecImmune release

> OncoGenex has started a Phase II trial of its drug, OGX-427, in men with advanced prostate cancer. All of the patients have never received chemotherapy. The study will evaluate OGX-427 as part of prostate cancer treatment and its effect on prostate specific antigen (PSA) levels and other prostate cancer warning signs. OncoGenex release

And Finally... Merck ranked high on InformationWeek's 500 list. Report

Suggested Articles

Two years after it walked away from a Voyager Therapeutics-partnered Parkinson’s gene therapy, Sanofi Genzyme is at it again.

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

A University of Pennsylvania team discovered that a protein called TOX helps determine the fate of exhausted T cells in cancer and other diseases.